Sawyer & Company Inc Acquires Shares of 29,767 Pfizer Inc. (PFE)
Sawyer & Company Inc acquired a new position in Pfizer Inc. (NYSE:PFE) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 29,767 shares of the biopharmaceutical company’s stock, valued at approximately $1,078,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer during the second quarter valued at approximately $103,000. Herndon Capital Management LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $120,000. Americafirst Capital Management LLC bought a new stake in shares of Pfizer during the third quarter valued at approximately $127,000. Private Vista LLC raised its stake in shares of Pfizer by 2,277.3% during the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 190,933 shares in the last quarter. Finally, Lipe & Dalton raised its stake in shares of Pfizer by 6.9% during the second quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after acquiring an additional 300 shares in the last quarter. 70.43% of the stock is owned by institutional investors and hedge funds.
Pfizer Inc. (NYSE PFE) opened at $36.77 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.35 and a debt-to-equity ratio of 0.47. Pfizer Inc. has a 1-year low of $31.67 and a 1-year high of $39.43. The stock has a market cap of $218,890.00, a price-to-earnings ratio of 21.01, a price-to-earnings-growth ratio of 2.06 and a beta of 0.91.
Pfizer declared that its board has initiated a stock buyback program on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.
The company also recently declared a quarterly dividend, which was paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd were issued a $0.34 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.70%. The ex-dividend date was Thursday, February 1st. Pfizer’s payout ratio is currently 77.71%.
In other Pfizer news, insider Charles H. Hill sold 42,393 shares of Pfizer stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $35.76, for a total value of $1,515,973.68. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the transaction, the executive vice president now directly owns 46,963 shares in the company, valued at $1,740,918.41. The disclosure for this sale can be found here. Insiders sold 115,765 shares of company stock worth $4,217,653 over the last ninety days. Corporate insiders own 0.06% of the company’s stock.
Several analysts have recently weighed in on the stock. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, January 30th. SunTrust Banks reissued a “hold” rating and issued a $40.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Morgan Stanley boosted their price objective on shares of Pfizer from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. UBS Group set a $42.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Finally, Societe Generale set a $40.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. Pfizer currently has an average rating of “Hold” and a consensus price target of $39.40.
TRADEMARK VIOLATION NOTICE: “Sawyer & Company Inc Acquires Shares of 29,767 Pfizer Inc. (PFE)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2018/03/11/sawyer-company-inc-acquires-shares-of-29767-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.